Publication
Article
BioPharm International
Extractables and Leachables: Determining Risk in Single-Use Systems
Author(s):
As SUS become prevalent in the biologics industry, the question of safety becomes increasingly important.
Single-use systems (SUS) are increasingly becoming the norm in biologics development and manufacturing. Approximately 85% of the pre-commercial biopharmaceutical sector use SUS, and they are increasingly being adopted for commercial manufacturing. SUS have significant advantages but are not without drawbacks. A 2018 survey showed that 73.3% of biologics insiders listed contamination from extractables and leachables to be a major problem.
Read this article in BioPharm International's Single-Use Systems 2019 eBook.
Article Details
BioPharm International
eBook: Single-Use Systems 2019
Vol. 32
June 2019
Pages: 20–23
Citation
When referring to this article, please cite it as A. Nixdorf, "Extractables and Leachables: Determining Risk in Single-Use Systems," BioPharm International Single-Use Systems eBook (June 2019).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
